Arvinas Inc (ARVN)vsVertex Pharmaceuticals Inc (VRTX)
ARVN
Arvinas Inc
$8.45
-2.99%
HEALTHCARE · Cap: $545.20M
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3874% more annual revenue ($12.59B vs $316.70M). VRTX leads profitability with a 35.0% profit margin vs 2.9%. VRTX trades at a lower P/E of 30.0x. VRTX earns a higher WallStSmart Score of 64/100 (C+).
ARVN
Buy56
out of 100
Grade: C
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARVN.
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 66.4%
Revenue surging 1015.0% year-over-year
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 1.6% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARVN
The strongest argument for ARVN centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1015.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ARVN
The primary concerns for ARVN are P/E Ratio, EPS Growth, Market Cap. Thin 2.9% margins leave little buffer for downturns.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ARVN profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
ARVN carries more volatility with a beta of 1.76 — expect wider price swings.
ARVN is growing revenue faster at 1015.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 56/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arvinas Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?